JianLi(Li)CampianMD

Oncology • Rochester, MN

Physician

Join to view full profile

Dr. Campian is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Campian's full profile

Already have an account?

Office
200 1st St SW
Rochester, MN 55905
Phone+1 507-284-2511

Education & Training

Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
Zucker School of Medicine at Hofstra/NorthwellResidency, Internal Medicine, 2007 - 2010
Tianjin Medical UniversityClass of 1997

Certifications & Licensure

IL State Medical License 2020 - 2026
MN State Medical License 2021 - 2025
SC State Medical License 2021 - 2025
MO State Medical License 2013 - 2022
MD State Medical License 2010 - 2014
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Clinical Trials

Safety & Efficacy Study of TPI 287 + Avastin in Adults With Glioblastoma That Progressed Following Prior Avastin Therapy Start of enrollment: 2014 Jan 01
Terminated
Phase 2
Falls Risk Questionnaire in Older Adults With Cancer Start of enrollment: 2014 Aug 01
Completed
Study of the Effect NT-I7 on CD4 Counts in Patients With High Grade Gliomas Start of enrollment: 2018 Oct 30
Terminated
Phase 1
Temozolomide Chronotherapy for High Grade Glioma Start of enrollment: 2016 Aug 11
Active, not recruiting
Phase 2
Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas Start of enrollment: 2017 Jan 01
Withdrawn
Early Phase 1
Retifanlimab and Epacadostat in Combination With Radiation and Bevacizumab in Patients With Recurrent Gliomas Start of enrollment: 2020 Apr 20
Active, not recruiting
Phase 2
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temzolomide Start of enrollment: 2019 Jan 04
Recruiting
Phase 1, Phase 2
Join now to see all

Publications & Presentations

PubMed

169 citations
Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A P...
Linda M Liau, Keyoumars Ashkan, Steven Brem, Jian L Campian, John E Trusheim
JAMA Oncology. 2023-01-01
31 citations
Long-Acting Recombinant Human Interleukin-7, NT-I7, Increases Cytotoxic CD8 T Cells and Enhances Survival in Mouse Glioma Models.
Jian L Campian, Subhajit Ghosh, Vaishali Kapoor, Ran Yan, Sukrutha Thotala
Clinical Cancer Research. 2022-03-15
3 citations
Cerebrospinal fluid 2-hydroxyglutarate as a monitoring biomarker for IDH-mutant gliomas.
Cecile Riviere-Cazaux, Jean M Lacey, Lucas P Carlstrom, William J Laxen, Amanda Munoz-Casabella
Neuro-Oncology Advances. 2023-05-11

Lectures

Effect of a novel long-acting interleukin-7 agonist, NT-I7, on survival in mouse models of glioma.
2019 ASCO Annual Meeting - 6/1/2019

Press Mentions

Is Chronochemotherapy Coming?October 5th, 2022
Plymouth Paper, Gamma Tiles and HypertensionSeptember 24th, 2022
Does the Timing of Cancer Chemotherapy Appointments Matter?September 20th, 2022
Join now to see all